神经科指南

订阅

MedSci主页 / 所有栏目 / 神经科指南

2022 国际共识：阿尔茨海默病tau PET显像剂¹⁸F-flortaucipir检查

2022-01-03 国外影像科相关专家小组 Eur J Nucl Med Mol Imaging

神经阿尔茨海默病tau PET显像剂¹⁸F-flortaucipir检查

正电子发射断层扫描（PET）是证实阿尔茨海默病(AD)的潜在神经病理变化的最有效手段。

中文标题：

2022 国际共识：阿尔茨海默病tau PET显像剂¹⁸F-flortaucipir检查

英文标题：

International consensus on the use of tau PET imaging agent ¹⁸F-flortaucipir in Alzheimer's disease

发布机构：

国外影像科相关专家小组

发布日期：

2022-01-03

简要介绍：

正电子发射断层扫描（PET）是证实阿尔茨海默病(AD)的潜在神经病理变化的最有效手段。tau PET显像剂¹⁸F-flortaucipir已被FDA批准用于脑部正电子发射断层扫描（PET）成像检查，以评估阿尔茨海默（AD）、伴有认知损害的成人患者，确定脑部聚集性tau神经纤维缠结（NFT）的密度和分布。 本文主要针对tau PET显像剂¹⁸F-flortaucipir成像检查提供共识指导。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2022 国际共识：阿尔茨海默病tau+PET显像剂¹⁸F-flortaucipir检查.pdf)] GetToolGuiderByIdResponse(projectId=1, id=8f3b21c00231109d, title=2022 国际共识：阿尔茨海默病tau PET显像剂¹⁸F-flortaucipir检查, enTitle=International consensus on the use of tau PET imaging agent ¹⁸F-flortaucipir in Alzheimer's disease, guiderFrom=Eur J Nucl Med Mol Imaging, authorId=0, author=, summary=正电子发射断层扫描（PET）是证实阿尔茨海默病(AD)的潜在神经病理变化的最有效手段。, cover=https://img.medsci.cn/202215/1641352777690_1608702.jpg, journalId=0, articlesId=null, associationId=1569, associationName=国外影像科相关专家小组, associationIntro=, copyright=0, guiderPublishedTime=Mon Jan 03 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">正电子发射断层扫描（PET）是证实阿尔茨海默病(AD)的潜在神经病理变化的最有效手段。tau PET显像剂&sup1;⁸F-flortaucipir已被FDA批准用于脑部正电子发射断层扫描（PET）成像检查，以评估阿尔茨海默（AD）、伴有认知损害的成人患者，确定脑部聚集性tau神经纤维缠结（NFT）的密度和分布。 本文主要针对tau PET显像剂&sup1;⁸F-flortaucipir成像检查提供共识指导。</span></p>, tagList=[TagDto(tagId=614, tagName=神经), TagDto(tagId=787, tagName=阿尔茨海默病), TagDto(tagId=120866, tagName=tau PET显像剂¹⁸F-flortaucipir检查)], categoryList=[CategoryDto(categoryId=17, categoryName=神经科, tenant=100), CategoryDto(categoryId=40, categoryName=影像放射, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=787, guiderKeyword=阿尔茨海默病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4906, appHits=67, showAppHits=0, pcHits=749, showPcHits=4839, likes=4, shares=6, comments=4, approvalStatus=1, publishedTime=Wed Jan 05 11:16:59 CST 2022, publishedTimeString=2022-01-03, pcVisible=1, appVisible=1, editorId=1608702, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=dajiong, createdTime=Wed Jan 05 11:20:12 CST 2022, updatedBy=1608702, updatedName=dajiong, updatedTime=Sat Jan 06 21:37:37 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2022 国际共识：阿尔茨海默病tau+PET显像剂¹⁸F-flortaucipir检查.pdf)])
2022 国际共识：阿尔茨海默病tau+PET显像剂¹⁸F-flortaucipir检查.pdf
下载请点击：
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1185900, encodeId=a37b1185900b0, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b621494053, createdName=drheys, createdTime=Wed Jan 19 08:14:46 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182061, encodeId=cf671182061d1, content=新标准新应用快推广, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc861326333, createdName=zyyywebmaster, createdTime=Sat Jan 08 03:38:00 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181150, encodeId=560d1181150ad, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Thu Jan 06 07:25:35 CST 2022, time=2022-01-06, status=1, ipAttribution=)]
    2022-01-19 drheys

    学习学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1185900, encodeId=a37b1185900b0, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b621494053, createdName=drheys, createdTime=Wed Jan 19 08:14:46 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182061, encodeId=cf671182061d1, content=新标准新应用快推广, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc861326333, createdName=zyyywebmaster, createdTime=Sat Jan 08 03:38:00 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181150, encodeId=560d1181150ad, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Thu Jan 06 07:25:35 CST 2022, time=2022-01-06, status=1, ipAttribution=)]
    2022-01-08 zyyywebmaster

    新标准新应用快推广

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1185900, encodeId=a37b1185900b0, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b621494053, createdName=drheys, createdTime=Wed Jan 19 08:14:46 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182061, encodeId=cf671182061d1, content=新标准新应用快推广, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc861326333, createdName=zyyywebmaster, createdTime=Sat Jan 08 03:38:00 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181150, encodeId=560d1181150ad, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Thu Jan 06 07:25:35 CST 2022, time=2022-01-06, status=1, ipAttribution=)]
    2022-01-06 微探

    学习学习

    0

相关指南

2021 国际共识：[¹⁸F]-FDG PET/CT检查在儿童癫痫患者中的应用

国外神经内科相关专家小组（统称） · 2021-11-20

胎儿中枢神经系统产前超声检查专家共识（2020）

四川大学华西第二医院超声科 · 2021-05-01

2021 循证指南：肘部尺神经病变的神经肌肉超声诊断

国外影像科相关专家小组 · 2021-12-17

2017 EAU指南：神经泌尿学

欧洲泌尿外科学会(EAU,European Association of Urology) · 2017-03-01

2017 NANETS共识指南：手术治疗小肠神经内分泌肿瘤

北美神经内分泌肿瘤学会(NANETS,North American Neuroendocrine Tumor Society) · 2017-06-10

2017 NANETS共识指南：中肠神经内分泌肿瘤的监测和医学管理

北美神经内分泌肿瘤学会(NANETS,North American Neuroendocrine Tumor Society) · 2017-06-10

拓展阅读

2016 阿尔茨海默病创新药物临床试验中国专家共识

中国神经内科相关专家小组（统称） · 2016-02-29

2018中国痴呆与认知障碍诊治指南（二）：阿尔茨海默病诊治指南

中国医师协会神经内科医师分会 · 2018-04-03

阿尔茨海默病的中医诊疗共识

中华中医药学会(CACM,China Association of Chinese Medcine) 脑病分会 · 2018-05-02

2018中国痴呆与认知障碍诊治指南(七)：阿尔茨海默病的危险因素及其干预

中国医师协会神经内科医师分会 · 2018-05-22

2018中国痴呆与认知障碍诊治指南（六）：阿尔茨海默病痴呆前阶段

中国医师协会神经内科医师分会 · 2018-05-22

中国阿尔茨海默病临床前期主观认知下降诊断流程与规范专家共识

暂未更新 · 2019-02-12